Biomarin Pharmaceutical Inc. (BMRN)
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Ascendis Challenges BioMarin, But Market Response Seems Excessive
Ascendis' TransCon CNP showed similar efficacy to BioMarin's Voxzogo, but offers once-weekly dosing, potentially improving patient adherence. The achondroplasia market is significant, with potential annual revenues approaching $1 billion, but competition may impact market share. Ascendis faces financial challenges, including a cash runway of approximately 15 months and a current ratio below 1.0.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years
BMRN divulges ambitious plans for business growth over the next 10 years. It expects yearly sales to grow at a mid-teen rate through 2034.
Why Is BioMarin (BMRN) Up 5.4% Since Last Earnings Report?
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?
Bet on These 5 Stocks With Upgraded Broker Ratings Right Now
Brokers have deeper insights into stocks and the macroeconomic backdrop. One must follow broker rating upgrades to pick stocks like WWW, BMRN, DDOG, PGR & KVYO.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BioMarin to reduce global workforce by about 225 employees
BioMarin Pharmaceutical will reduce its global workforce by about 225 employees, a filing showed on Wednesday.
Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes"
BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market.
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is the Options Market Predicting a Spike in BioMarin (BMRN) Stock?
Investors need to pay close attention to BioMarin (BMRN) stock based on the movements in the options market lately.
BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024
BioMarin Pharmaceutical Inc. sales of Voxzogo had increased by 62% to $184 million in Q2 of 2024, compared to the same period in 2023. Potential to eventually expand the use of Voxzogo towards other indications like hypochondroplasia and idiopathic short stature. Data from the phase 1/2 study, using BMN351 for the treatment of patients with DMD amenable to exon 51 skipping, expected by the end of 2024.
